PMID- 11208826
OWN - NLM
STAT- MEDLINE
DCOM- 20010329
LR  - 20220409
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 19
IP  - 2
DP  - 2001 Jan 15
TI  - Her-2/neu analysis in archival tissue samples of human breast cancer: comparison 
      of immunohistochemistry and fluorescence in situ hybridization.
PG  - 354-63
AB  - PURPOSE: The objective of our study was to compare the methods used in the 
      literature to analyze HER-2/neu status on archival breast cancer tissue. 
      Therefore, a series of antibodies was evaluated to assess their 
      immunohistochemical (IHC) sensitivity in correlation to gene amplification 
      determined by fluorescence in situ hybridization (FISH). MATERIALS AND METHODS: 
      HER-2/neu overexpression was studied on paraffin sections of 85 invasive breast 
      cancers using a panel of five monoclonal (9G6, 3B5, CB11, TAB250, GSF-HER2) and 
      two polyclonal antibodies (A8010, A0485) in addition to the HercepTest (DAKO, 
      Glostrup, Denmark). HER-2/neu gene amplification was determined by FISH using a 
      dual-color probe (PathVysion; Vysis, Stuttgart-Fasanenhof, Germany). RESULTS: 
      HER-2/neu overexpression was demonstrated in 26% (9G6, TAB250, GSF-HER2), 27% 
      (3B5, CB11), 33% (A8010) and 42% (A0485, HercepTest) of the tumors. FISH on 
      paraffin sections identified gene amplification in 28% of the tumors. Strongly 
      positive IHC results (3+) were always associated with gene amplification. Among 
      the 16 tumors presented with weakly positive IHC results (2+) using the 
      HercepTest, 12 (75%) lacked gene amplification. CONCLUSION: The comparison of IHC 
      and FISH demonstrated an excellent correlation of high-level HER-2/neu 
      overexpression (3+) with gene amplification; ie, FISH does not provide further 
      information in these tumors. However, weakly positive IHC results (2+) obtained 
      with the HercepTest share only a minor association with gene amplification.
FAU - Lebeau, A
AU  - Lebeau A
AD  - Pathologisches Institut and Klinik fur Frauenheilkunde und Geburtshilfe 
      Klinikum-GroBhadern, Ludwig-Maximilians-Universitat, Munchen, Germany. 
      a.lebeau@lrz.uni-muenchen.de
FAU - Deimling, D
AU  - Deimling D
FAU - Kaltz, C
AU  - Kaltz C
FAU - Sendelhofert, A
AU  - Sendelhofert A
FAU - Iff, A
AU  - Iff A
FAU - Luthardt, B
AU  - Luthardt B
FAU - Untch, M
AU  - Untch M
FAU - Lohrs, U
AU  - Lohrs U
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Antibodies, Monoclonal)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Antibodies, Monoclonal
MH  - Breast Neoplasms/genetics/*metabolism/pathology
MH  - Gene Amplification
MH  - Genes, erbB-2
MH  - Humans
MH  - *Immunohistochemistry
MH  - *In Situ Hybridization, Fluorescence
MH  - Nucleic Acid Amplification Techniques
MH  - Receptor, ErbB-2/immunology/*metabolism
EDAT- 2001/02/24 11:00
MHDA- 2001/04/03 10:01
CRDT- 2001/02/24 11:00
PHST- 2001/02/24 11:00 [pubmed]
PHST- 2001/04/03 10:01 [medline]
PHST- 2001/02/24 11:00 [entrez]
AID - 10.1200/JCO.2001.19.2.354 [doi]
PST - ppublish
SO  - J Clin Oncol. 2001 Jan 15;19(2):354-63. doi: 10.1200/JCO.2001.19.2.354.